Blockade of the histamine H 3 receptor (H 3 R) enhances central neurotransmitter release, making it an attractive target for the treatment of cognitive disorders. Here, we present in vitro and in vivo pharmacological profiles for the
Introduction
Histamine is a biogenic amine that is recognized as an important neurotransmitter involved in a number of physiological responses in humans. The variety of effects mediated by histamine is the result of the activation of H 1 , H 2 , H 3 , and H 4 receptor subtypes. The specificity of histamine responses depends on the differential pharmacology, molecular biology, signal transduction characteristics, and localization exhibited by these four receptors (Hough, 2001; Bakker et al., 2002; Haas et al., 2008) . H 1 and H 2 receptor antagonists have been very successful therapeutic agents in the treatment of allergic reactions and gastric ulcers, respectively.
Histamine is an important neurotransmitter in the CNS, regulating a variety of functions including attention, cognition, sleep, and weight homeostasis (Passani et al., 2004; Esbenshade et al., 2008; Brioni et al., 2011) . Histamine is released from histaminergic neurons that originate in the hypothalamic tuberomammillary nucleus and project throughout most of the brain including cortex, striatum, thalamus, hippocampus, locus These studies were funded by Abbott Laboratories. Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
http://dx.doi.org/10. 1124/jpet.112.194126. ABBREVIATIONS: CNS, central nervous system; H 3 R, H 3 receptor; AD, Alzheimer's disease; SHR, spontaneously hypertensive rat; (R)-␣-MeHA, (R)-␣-methylhistamine; HEK, human embryonic kidney; EFS, electric field stimulation; GTP␥S, guanosine 5Ј-O-(3-thio)triphosphate; ANOVA, analysis of variance; hERG, human ether-a-go-go-related gene; Veh, vehicle; 6aR )-5-methyl-hexahydro-pyrrolo [3,4-b] pyrrol-1-yl)-biphenyl-4-yl]-2H-pyridazin-3-one; BF2.649, 1- (3-(3-(4-chlorophenyl) propoxy)propyl)piperidine; GSK189254, 6-((3-cyclobutyl-2,3,4 ,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide; GSK207040, 5-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl) coeruleus, and spinal cord. The H 3 R was originally described as a presynaptic autoreceptor that, when stimulated, inhibits the release of histamine in the brain (Arrang et al., 1983) . It also functions as a heteroreceptor that can inhibit the release of other neurotransmitters (Schlicker et al., 1988 (Schlicker et al., , 1989 (Schlicker et al., , 1993 Clapham and Kilpatrick, 1992; Blandina et al., 1996; Baldi et al., 2005) . The H 3 R is localized in rodent and human brain regions, with high expression in both species in the prefrontal cortex, hippocampus, and hypothalamus, regions that are associated with histaminergic innervation and responsible for learning, memory, and sleep (Martinez-Mir et al., 1990; Lovenberg et al., 1999; Drutel et al., 2001) . It is well established that histamine H 3 R antagonists can enhance the release of multiple neurotransmitters involved in vigilance, alertness, and cognition enhancement including histamine by blockade of H 3 autoreceptors (Arrang et al., 1983) as well as the release of acetylcholine, norepinephrine, dopamine, and serotonin via the blockade of H 3 heteroreceptors (Arrang et al., 1983; Blandina et al., 1998) . These findings, in addition to the wide central nervous system projection of histaminergic neurons and localized expression of H 3 Rs in cortical and limbic system areas, have made this receptor an attractive drug target for treating cognitive dysfunctions such as Alzheimer's disease (AD), attention deficit hyperactivity disorder, and cognitive deficits of schizophrenia (Esbenshade et al., 2006 (Esbenshade et al., , 2008 Browman et al., 2009; Celanire et al., 2009; Passani et al., 2009; Brioni et al., 2011) .
Considerable efforts have been expended to developing H 3 R antagonists. First, imidazole-based H 3 R antagonists such as thioperamide (Arrang et al., 1987) , ciproxifan (Ligneau et al., 1998) , clobenpropit (Barnes et al., 1993) , and cipralisant (Tedford et al., 1998) were made, and although they were useful pharmacological tools, they suffered pharmacokinetic and metabolic issues that halted their development as human therapeutics (Esbenshade et al., 2008) . More recently, novel selective nonimidazole H 3 R antagonists (Esbenshade et al., 2008; Celanire et al., 2009; Leurs et al., 2011) , including pitolisant [1- (3-(3-(4-chlorophenyl) propoxy)propyl)piperidine (BF2.649)], 6-( (3-cyclobutyl-2,3,4, 5-tetrahydro-1H-3-benzazepin-7-yl) oxy)-N-methyl-3-pyridinecarboxamide (GSK189254), 5-((3-cyclobutyl-2,3,4, 5-tetrahydro-1H-3-benzazepin-7-yl) oxy)-N-methyl-2-pyrazinecarboxamide (GSK207040), 2-methyl-3-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-5-trifluoromethyl-3H-quinazolin-4-one (MK-0249), 1-{3-[4-(piperidin-1-ylmethyl)phenoxy]propyl}pi-peridine (JNJ-17216498) , and irdabisant [6-(4-(3-(2-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-pyridazin-3-one (CEP-26401)] have been advanced to early human trials for a variety of indications. Although preclinical data for some of these compounds are limited, pitolisant has been reported to increase acetylcholine and dopamine release in the rat cortex, reverse the cognitive deficits induced by scopolamine in the object recognition model, and exhibit antipsychotic potential in animal models (Ligneau et al., 2007a,b; Schwartz, 2011) . Both GSK189254 and GSK207040 have been shown to enhance neurotransmitter release in rat cortex (Medhurst et al., 2007; Southam et al., 2009 ). GSK189254 reversed scopolamine-induced amnesia in an inhibitory avoidance assay and has shown efficacy in water maze and object recognition tests (Medhurst et al., 2007) , whereas irdabisant improved performance in the rat social recognition model of short-term memory (Raddatz et al., 2012) . We reported previously that 4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile (ABT-239) Fox et al., 2005 ) is a potent and selective H 3 R antagonist, but cardiovascular safety issues precluded its advancement to the clinic.
In this article, we show the in vitro pharmacological profile and broad preclinical efficacy of the H 3 R antagonist 2-[4Ј-((3aR,6aR)-5-methyl-hexahydro-pyrrolo [3,4-b] pyrrol-1-yl)-biphenyl-4-yl]-2H-pyridazin-3-one (ABT-288) (Fig. 1 ), a compound with high affinity and selectivity for human histamine H 3 Rs.
Materials and Methods
Chemicals ABT-288 (Cowart et al.; WO2007/100990;  Fig. 1 ), ABT-239, 
Animals
Male spontaneously hypertensive rat (SHR) pups for repeated acquisition avoidance studies were obtained from Harlan (Indianapolis, IN) at postnatal day 7 and housed at Abbott Laboratories until their use on postnatal days 20 to 24 (body weights ranged from 35 to 50 g). Pups were housed up to 12 per cage (average of two litters) and fostered with Long-Evans lactating females (two per cage), largely to avoid the poor maternal care of SHR females and possible associated effects on brain and cognitive development (Fox et al., 2002) . Adult (350 -450 g) and juvenile (75-100 g) male Sprague-Dawley rats for social recognition studies, adult (250 -350 g) male Sprague-Dawley rats for in vitro tissue assays and general observation studies, and adult Long-Evans rats for water maze studies (300 -400g) were obtained from Charles River Breeding Laboratories (Portage, MI). Sprague-Dawley rats for microdialysis studies (350 -380 g) were purchased from Elevage Janvier (LeGenest Saint Isle, France). Male CD-1 mice were obtained from Charles River Breeding Laboratories at approximate 20 to 25 g body weight for methamphetamine hyperactivity studies. All rodents were housed in a quiet room under conditions of 12-h lights on/off (on at 6:00 AM), with food and water available ad libitum. Rats for EEG studies were housed singly. Male Hartley guinea pigs (weighing from 150 -200 g on arrival) were supplied by Charles River Breeding Laboratories. All testing occurred during the light phase, and all experiments were conducted in accordance with guidelines from the Abbott Animal Care and Use Resources, 1996) in facilities accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care. The animals were acclimated to laboratory conditions for at least 1 week before testing in a temperature-regulated environment with lights on between 6:00 AM and 6:00 PM.
ABT-288

Radioligand Binding Assays
For H 3 R competition binding, membrane preparations were made from human embryonic kidney (HEK) cells expressing the full-length (445 amino acids) human histamine H 3 R (Lovenberg et al., 1999) and the full-length rat histamine H 3 R and brain cerebral cortices from humans (Analytical Biological Services, Wilmington, DE) and rats and mice (Pelfreez, Rogers, AR) as described previously . Membranes were incubated with [
3 H]N-␣-methylhistamine (0.5-1.0 nM) in the presence or absence of increasing concentrations (from 5 to 11 concentrations over a five-log unit range) of competing ligands for 30 min at 25°C in a final volume of 0.5 ml of 50 mM Tris/5 mM EDTA, pH 7.4 buffer as described previously Strakhova and Esbenshade, 2007) . Nonspecific binding was defined with 10 M thioperamide. Cloned human histamine H 1 , H 2 , and H 4 receptor radioligand binding assays were performed as described previously Strakhova and Esbenshade, 2007) 3 H]histamine, respectively. All binding reactions were terminated by vacuum filtration onto polyethylenimine (0.3%) presoaked Unifilter plates (PerkinElmer Life and Analytical Sciences) or Whatman GF/B filters (for human cortex H 3 R and human H 4 receptor) followed by three brief washes with 2 ml of ice-cold 50 mM Tris/5 mM EDTA buffer. Liquid scintillation counting was used to determine bound ligand.
IC 50 values and Hill slopes were determined by Hill transformation for all of the radioligand competition binding data as described previously (Strakhova and Esbenshade, 2007) . K i values were determined by the Cheng-Prusoff equation (Cheng and Prusoff, 1973) , and the data are presented as the mean K i with 95% confidence intervals. The data were reanalyzed by using GraphPad Prism (GraphPad Software, Inc., San Diego, CA) and best-fit to a one-site binding curve.
Receptor Occupancy Studies
Receptor occupancy by ABT-288 was assessed by an established in vivo method using the H 3 antagonist ligand [
3 H]A-349821 as radiotracer (Miller et al., 2009) . Various doses of unlabeled ABT-288 were administered intraperitoneally in a volume of 1 ml/kg, and [
3 H]A-349821 (1.5 g/kg i.v.) was subsequently administered 30 min later. After an additional 30 min postdosing, the rats were anesthetized with CO 2 and decapitated, and blood and brain tissues were collected for quantification of unlabeled 3 H]A-349821 distribution ratio of each individual rat by using the following formula: percentage of H 3 receptor occupancy ϭ 100 Ϫ (ctx/cb ratio Ϫ 1)/ (average control ctx/cb ratio Ϫ1) ϫ 100, where ctx and cb are cortex and cerebellum, respectively.
The average percentages of receptor occupancy values (Ϯ S.E.M.) were plotted versus the antagonist dose, and an ED 50 for receptor occupancy was determined by nonlinear regression by using the equation for sigmoidal dose response. Likewise, the percentages of receptor occupancy values from individual rats were plotted versus ABT-288 levels, and an ED 50 was determined and reported as nanogram per milliliter of plasma. In all cases, GraphPad Prism software was used for nonlinear regression analysis.
Electric Field-Stimulated Guinea Pig Ileal Segments
The reversal of (R)-␣-MeHA-mediated inhibition of EFS (test voltage ϳ7-8V; 0.1-Hz frequency; 0.5-ms duration) elicited twitches of guinea pig ileal segments by H 3 R antagonists was determined as described previously (Ireland-Denny et al., 2001; Esbenshade et al., 2005) . Various concentrations of H 3 R antagonists were added to the tissue baths 30 min before the generation of (R)-␣-MeHA cumulative concentration response curves, and the potency (pA 2 ) of the antagonists to inhibit the (R)-␣-MeHA response was calculated according to the method of Schild (1947) ) as described previously (Ireland-Denny et al., 2001; Esbenshade et al., 2005) .
Rat Cerebral Cortical Histamine Release Assay
The ability of H 3 R antagonists to reverse histamine-mediated inhibition of [ 3 H]histamine release from rat cerebral cortical synaptosomes evoked by potassium (15 mM) was determined as described previously (Arrang et al., 1985; Esbenshade et al., 2005) . Synaptosomes (approximately 2 mg of protein) were added to microcentrifuge tubes containing 1 M of the agonist histamine (EC 50 ϭ 34 nM) either alone or together with ABT-288, and the mixture was incubated for 2 min at 37°C. Potassium (15 mM final concentration) was subsequently added, and the samples were incubated for an additional 2 min before the incubation was terminated. Values for the basal release of [ 3 H]histamine (obtained in buffer without additional potassium) were subtracted from each sample, and the data were expressed as a percentage of the maximum potassium-stimulated release for each assay. Experiments were performed in triplicate, and data were analyzed by using GraphPad Prism to obtain IC 50 values and Hill slopes. pK b values were determined by the generalized Cheng-Prusoff equation (Cheng and Prusoff, 1973; Leff and Dougall, 1993) and are presented as the mean Ϯ S.E.M.
[ 35 S]GTP␥S Binding Assay
HEK cell membranes expressing the human H 3 R or C6 cell membranes expressing the rat H 3 R were prepared by homogenization in cold buffer containing 50 mM Tris-HCl, pH 7.4, 5 mM EDTA, 10 mM MgCl 2 , and protease inhibitors. The homogenate was centrifuged two times at 40,000g for 20 min at 4°C, and the resulting pellet was resuspended in buffer containing 50 mM Tris-HCl, pH 7.4, 5 mM EDTA, and 10 mM MgCl 2 . Glycerol and bovine serum albumin were added to a final concentration of 10% glycerol and 1% bovine serum albumin before freezing the membranes. The inverse agonist activity of H 3 R antagonists was determined as described previously . In brief, membranes were diluted in GTP␥S assay buffer (25 mM HEPES, 2.5 mM MgCl 2 , and 75 mM NaCl, pH 7.4), and 10 g of membrane protein was incubated in a 96-well deep-well block in the presence of 5.0 M unlabeled GDP, approximately 0.5 nM of [ 35 S]GTP␥S, and various concentrations of H 3 R antagonists. Samples were subsequently incubated at 37°C for 20 min. For assays to determine antagonist activity, (R)-␣-MeHA (30 nM for human and 300 nM for rat H 3 R) was added in addition to the assay components described above, and the samples were incubated at 37°C for 5 min. The assays were terminated by the addition of cold buffer (50 mM Tris-HCl, 75 mM NaCl, and 2.5 mM MgCl 2 , pH 7.6) and subsequent harvesting by vacuum filtration onto a Packard Unifilter 96-well GF/B plate (PerkinElmer Life and Analytical Sciences). After extensive washing, the plates were dried, Microscint 20 was added to the samples, and the amount of bound [
35 S]-GTP␥S was determined by using Topcount (PerkinElmer Life and Analytical Sciences). The bound [
35 S]GTP␥S in each sample was expressed as a percentage of that bound to control samples incubated in the absence of histamine H 3 R ligands. Triplicate determinations were obtained at each concentration, and the data were analyzed by using GraphPad Prism to obtain EC 50 values for inverse agonism. The potency (pA 2 ) of antag- onists to inhibit the (R)-␣-MeHA response was calculated according to the method of Schild (1947) . The mean Ϯ S.E.M. of at least three independent experiments is reported.
Microdialysate Levels of Acetylcholine, Dopamine, and Histamine
For pain prophylaxis, animals were dosed preoperatively with rimadyl (5 mg/kg i.p.). Individual male Sprague-Dawley rats (290 -320 g body weight) anesthetized with pentobarbital (60 mg/kg i.p.; Narcoren, Rhone-Merieux, Lyon, France) were mounted in a stereotaxic frame (David Kopf Instruments, Tujunga, CA), and microdialysis guide cannulas (CMA/12; Axel Semrau GmbH, Sprockhöve, Germany) were implanted into the medial prefrontal cortex (anterior-posterior, 2.5; medial-lateral, 0.6; tip of the 3-mm long active membrane, 3.2 mm below the brain surface) according to Paxinos and Watson (1998) . The guide cannulas were secured with dental cement (Technovit powder, Technovit polymerization starter fluid; Kulzer GmbH, Dormagen, Germany) and four anchor screws into the skull. The rats were allowed to recover from surgery for 5 to 7 days. The day before the experiment, each animal was transferred into a system allowing for free movement (CMA/120; Axel Semrau GmbH), consisting of a plastic bowl, wire attachment, counter balance arm, and swivel assembly connecting in-/outlet of the probe with the perfusion pump. Next, a CMA/12 microdialysis probe (3-mm membrane length) was slowly lowered into the final position. The probe was perfused with Ringer's solution (147 mM NaCl, 4.0 mM KCl, and 2.4 mM CaCl 2 , containing 0.1 M neostigmine for the acetylcholine microdialysis study) for approximately 1 h (CMA/102 microdialysis pump, Axel Semrau GmbH; 1.5 l/min). The probe was perfused again 24 h later for at least 1 h before microdialysate fractions were collected every 20 min. On the day of the experiment, ABT-288 or its vehicle (2 ml/kg) was administered intraperitoneally. Six fractions before and six fractions after the intraperitoneal administration of the test compound or vehicle were analyzed for microdialysate levels of dopamine or acetylcholine by high-performance liquid chromatography with electrochemical detection.
Assay of Microdialysate Acetylcholine Levels
Ten microliters of each microdialysate fraction was injected onto a reversed-phase column (MF 8908 Acetylcholine SepStik Kit; microbore column, particle size 10 mm, 530 ϫ 1.0 m coupled to an immobilized enzyme reactor 50 ϫ 1.0 mm, particle size 10 m, containing acetylcholinesterase and choline oxidase; BAS Bioanalytical Systems, West Lafayette, IN) using a refrigerated autosampler (HTC PAL twin injector autosampler system; Axel Semrau GmbH). The mobile phase consisted of 50 mM Na 2 HPO 4 , pH 8.5, and 5 ml/l Kathon (Dow, Midland, MI). Flow rate was 0.14 ml/min (Rheos Flux pump; Axel Semrau GmbH), and the sample run time was less than 15 min. Acetylcholine and choline were measured via an electrochemical detector (LC-4C; BAS Bioanalytical Systems) with a platinum working electrode set at ϩ500 mV versus an Ag/AgCl reference electrode. The system was calibrated by standard solutions (acetylcholine and choline) containing 1 pmol/10 l injection. Acetylcholine was identified by its retention time and peak height with an external standard method using chromatography software (Chrom Perfect; Justice Laboratory Software, Denville, NJ). Microdialysis data (area under curve for time 0 -120 min was calculated by integration of the area by the trapezoidal rule) were evaluated for significance by using one-way analysis of variance (ANOVA) followed by Dunnett's pair wise comparison post hoc test using GraphPad Prism version 4.0 software.
Assay of Microdialysate Dopamine Levels
Ten microliters of each microdialysate fraction was injected onto a reversed-phase column (Nucleosil C18; Macherey-Nagel, Dü ren, Germany; 125 ϫ 4.0 mm; 3-m particle size) by using a refrigerated autosampler (HTC PAL twin injector autosampler system; Axel Semrau GmbH). The mobile phase consisted of 0.15 M/l NaH 2 PO 4 , 1 mM Na 2 EDTA, 0.23 mM sodium octylsulfate, 5 mM NaCl, and 4% isopropanol, pH 3.7. Flow rate was set to 0.75 ml/min (Rheos flux pump; Axel Semrau GmbH), and the sample run time was less than 15 min. Dopamine was measured via an electrochemical detector (Decade II; Axel Semrau GmbH) with a carbon glass working electrode (VT-03; Antec, Rotterdam, The Netherlands) and an ISAAC reference electrode (Antec). Oxidation currents were measured at a working potential of ϩ600 mV. The system was calibrated by standard solutions (dopamine, 3,4-dihydroxyphenylacetic acid, and homovanillic acid) containing 1 pmol/10 l injection. Dopamine was identified by its retention time and peak height with an external standard method using chromatography software. The chromatographic software and microdialysis statistics used were the same as above.
Assay of Microdialysate Histamine Levels
Animals were dosed preoperatively with banamine (2.5 mg/kg s.c.), anesthetized with isoflurane, and stereotaxically implanted with stainless-steel microdialysis guide cannulae (CMA/12) above the medial prefrontal cortex with the following coordinates (Paxinos and Watson, 1998) : anterior-posterior, ϩ2.8; medial-lateral, ϩ0.9; dorsal-ventral, Ϫ0.6. The cannulae were fixed in place by using skull screws and dental cement, the wounds were closed with 4-0 nonabsorbable suture, and the animals were allowed to recover for 3 to 7 days. The afternoon before the experiment, the animals were placed into individual cages and acclimated to handling. Microdialysis probes (CMA/12 Elite; 3-mm exposed probe) were inserted into the guide cannula, and rats were tethered to the liquid swivel lines and perfused overnight with artificial cerebrospinal fluid at a flow rate of 1.5 l/min. The next morning, 3 h of 20-min fractions (1.5 l/min) were collected, of which the last four were averaged and used for the baseline level of histamine. At time 0, animals were dosed with vehicle or ABT-288 (0.3 and 1 mg/kg i.p). Eleven sequential 20-min fractions (1.5 l/min) were collected and kept at 4°C. Animals were sacrificed, and the brains were examined histologically for verification of appropriate probe placement. Only animals with the desired probe placement were used for analysis. Samples were analyzed for histamine by liquid chromatography/mass spectrometry using an AB Sciex 5000 mass spectrometer (Applied Biosystems/MDS Sciex, Foster City, CA) with a SIELC Primesep 200 multidimensional column (SIELC Technologies, Prospect Heights, IL). No probe recovery adjustment was made. The microdialysis data calculations and statistics used were the same as above.
Five-Trial Inhibitory Avoidance in SHR Pup Studies
In this behavioral paradigm, hypothesized to test aspects of both attention and impulsivity, vehicle-treated rat pups showed an inability to withhold a natural response to transfer from the light into a preferred dark chamber. In the dose-response study, SHR rat pups were treated subcutaneously (5.0 ml/kg with ABT-288 or vehicle) 30 min before being placed into the brightly illuminated compartment of a two-compartment chamber (Hamilton Kinder, San Diego, CA), with a retractable door between the light and dark compartments opened. After animals transferred through the open door to the dark compartment, the door closed automatically, and a 0.1-mA scrambled current was applied to a 31-bar stainless-steel grid floor for 1 s. At this point the pup was removed and returned to its home cage and littermates for a 1-min intertrial interval, and the transfer latency was noted. The same pup was returned to the bright compartment, and the process was repeated for five trials. Plasma samples were collected from a separate set of pups dosed with ABT-288 with samples collected 40 to 45 min postinjection.
To assess the effect of drug on shock response thresholds, a separate experiment was conducted in which pups were treated with ABT-288 30 min before testing. Pups were placed in the light compartment with the door between the two compartments closed, and the current was slowly ramped up until the pup produced sustained vocalizations, after which the current was immediately ramped down until vocalizations ceased. These time points are referred to as iMAX and iMIN, respectively. To assess efficacy with repeated dosing, SHR pups were dosed for 5 days with an efficacious dose of ABT-288 (0.01 mg/kg s.c.). To further explore any effects of repeated dosing on efficacy, a second repeated-dosing study was conducted in which the maximally effective dose of ABT-288 (0.03 mg/kg s.c.) was administered for 4 days, and on day 5 the pups were dosed with 0.01 mg/kg s.c. ABT-288 and tested in the task 30 min later as described above in the acute assays. Data were analyzed by summing the responses from learning trials two to five. Statistical significance was determined by using two-tailed nonparametric Mann-Whitney U tests to compare drug treatment from vehicle (GraphPad Prism 4.0).
Adult Social Memory
Adult rats were trained in a social recognition memory test to recall prior exposure to a conspecific juvenile as described previously . In brief, adult rats (350 -450 g) were separated into fresh test cages and allowed to habituate for 30 min. An unfamiliar juvenile was introduced, and overall investigation duration (grooming, sniffing, and close following) was recorded for a 5-min period. Both rats were then removed to their respective holding cages. After 90 min, the adult was replaced into the test cage, the same juvenile was reintroduced 30 min later, and overall investigation duration was again recorded during a second 5-min period. ABT-288 or saline vehicle was administered intraperitoneally to the adult rat immediately after the first exposure period. To control for nonspecific effects, immediately after the second investigation period, a new, unfamiliar juvenile was introduced to the same adult rat for a third 5-min period, and overall investigation duration was recorded once again. Social memory was quantified by determining, for each adult rat, the ratio of investigation duration of the second to the first investigation periods. Nonspecific effects were assessed by determining the ratio of investigation duration (third to the first investigation periods) for the unfamiliar juvenile. To assess efficacy with repeated dosing, rats were dosed for 5 days with ABT-288 (0.03 mg/kg i.p.) and tested according to the protocol described above for this task. Trial 2 testing took place 2 h after the last injection, which was immediately after trial 1 as described above. Group sizes were 15 to 16 animals. Data were analyzed by using one-way ANOVA with Dunnett's post hoc analyses, comparing the response of drug-treated groups with the response of vehicle controls (GraphPad Prism 4.0).
Two-Choice Discrimination Water Maze
Adult male Long-Evans rats (Charles River Breeding Laboratories) were trained in a two-choice visual discrimination water maze test of spatial learning and reference memory as described previously . This version of the water maze is known to be sensitive to age, septal lesions, and scopolamine-induced impairments and is proposed as a model that may be pertinent to cognitive deficits associated with Alzheimer's disease. Two daily habituation sessions were conducted in which each rat was trained to find a visible escape platform in a pool (180 cm diameter and 60 cm high) filled to a depth of 37 cm with water made opaque with powdered milk. Water temperature was maintained at 26°C. On the second day of habituation training, a latency to escape measure was obtained to assure that animals are assigned to groups without swim speed bias. After a 2-day rest period, spatial discrimination testing was conducted by using two visually similar platforms, each covered in aluminum foil. The platforms remained in the same position through 5 days of training. However, only one of the platforms provided escape; the other (incorrect), made of Styrofoam, floated and did not support the weight of the animal. Each rat received six trials/day from one of the two starting positions that were alternated from trial to trial, and the number of contacts with the incorrect platform (errors) was recorded for each trial and averaged per day.
Drugs or vehicle control were administered intraperitoneally each day before training in a volume of 1.0 ml/kg. ABT-288 (0, 0.01, 0.1, or 1 mg/kg) or ABT-239 (1 mg/kg) was administered 15 min before scopolamine (0.3 mg/kg), and the animals were tested 15 min later. Data were compared over days by using a two-way, repeated-measures ANOVA. Subsequent one-way ANOVAs were used to evaluate errors for each of the 5 training days with Dunnett's post hoc analyses (GraphPad Prism 4.0).
Methamphetamine-Induced Hyperactivity
To evaluate the efficacy of ABT-288 in reversing methamphetamine-induced hyperactivity, mice were injected with ABT-288 (0.1, 0.3, or 1 mg/kg i.p.) or vehicle and placed separately into one of 16 acrylic open-field environments [42 (length) ϫ 42 (base) ϫ 40 cm (height); Piper Plastics, Libertyville, IL] situated inside Versamax/ Digiscan monitors, each equipped with 32 horizontal and 16 vertical infrared sensors (AccuScan Instruments, Inc., Columbus, OH) in a dimly illuminated test room. The mice were allowed to habituate while baseline activity data were recorded for 60 min at which point they were injected with methamphetamine (1.0 mg/kg i.p.) and monitored for another 90 min. Data were analyzed by using one-way ANOVA and Dunnett's post hoc test (GraphPad Prism 4.0).
Electroencephalogram Slow-Wave Activity
EEG recording electrodes were bilaterally implanted under pentobarbital anesthesia (50 mg/kg i.p.; Abbott Laboratories) over the parietal cortex (Ϫ2.0 mm anterior-posterior; 4.0 mm lateral) in 400-g male rats (Charles River Breeding Laboratories) maintained on a 12-h light/dark schedule. A reference electrode was placed 11 mm posterior to bregma, and a miniature connector was affixed to the skull. Implanted rats were allowed 2 weeks of recovery from the surgery before use. EEG (sampling rate 200 Hz) was recorded from previously habituated rats inside sound-attenuating chambers. Before experiments began, a flexible cable was attached to the implanted miniature connector that allowed the rats unrestricted movement during the recording sessions. Standard EEG amplifiers (Grass Instrument Division,, Astro-Med, West Warwick, RI) and a computer-based system (Stellate Systems, Montreal, Canada) were used to acquire and analyze data. The average EEG amplitude in microvolts was determined by using fast Fourier transform analysis and broken down into an analysis of the 1-to 4-Hz slow-wave band activity. Dose-response effects on EEG were determined for intraperitoneal administration of ABT-288 and compared with saline vehicle. The treatments were administered in a random order on different days with one treatment per day and 3 days between each treatment. On one of these treatment days, the rat would receive a vehicle control treatment. This within-subjects design allowed each rat to serve as its own control. EEG recordings were conducted during the light cycle and began within 5 min after injection, and recording sessions lasted for 120 min. A total of eight rats was used in these studies. 3 H]dofetilide in the presence or absence of increasing concentrations of ABT-288 for 45 min at 37°C in a final volume of 0.2 ml of Tris buffer as described previously (Diaz et al., 2004) . Isolated whole-cell patch-clamp electrophysiology experiments to determine IC 50 values for functional inhibition of hERG channel activity were performed as described previously (Diaz et al., 2004) . jpet.aspetjournals.org constant intravenous infusion of pentobarbital (6.0 mg/kg/h). Once anesthetized, the dogs were intubated with a cuffed endotracheal tube and ventilated with room air by means of a mechanical respiration pump (Harvard Apparatus Inc., Holliston, MA). Expiratory CO 2 was monitored with an end-tidal CO 2 monitor (Criticare Systems, Inc., Waukesha, WI) and maintained at 4 to 5% CO 2 . Electrocardiogram limb leads were attached to the animals, and a lead II ECG was recorded. A Swan-Ganz catheter (5.5 F; Hospira, Inc., Lake Forest, IL) was advanced into the pulmonary artery via the right jugular vein for measurement of cardiac output by using a cardiac output computer (Oximetrix 3; Abbott Laboratories). Central venous and pulmonary artery pressures were measured through the proximal and distal ports of the catheter, respectively. A dual tip micromanometer catheter (model SPC-770, 7F; Millar Instruments Inc., Houston, TX) was advanced into the left ventricle of the heart via the right carotid artery for the measurement of left ventricular and aortic blood pressure. Polyethylene catheters were inserted into the right femoral vein and artery for infusion of test agents and collection of blood samples, respectively. Systemic vascular resistance was calculated as [(mean arterial pressure Ϫ mean central venous pressure)/cardiac output]. Pulmonary vascular resistance was calculated as [(pulmonary arterial pressure Ϫ central venous pressure)/cardiac output]. Body temperature was monitored throughout the experiment.
Cardiovascular Parameters
The primary hemodynamic variables were computed by using commercial software and a signal processing workstation (Ponemah; Gould Instrument Systems, Inc., Cleveland, OH). The electronic lead II ECG record was assessed for changes in QT interval (QTc, corrected for heart rate using Fridericia's and Van de Water's formulae) and the PR interval via the Ponemah system with manual over-reads conducted at 15-min intervals (Polakowski et al., 2009 ). ABT-288 was dissolved in vehicle (polyethylene glycol 200, high-dose series or polyethylene glycol 400, low-dose series; Sigma) and administered by intravenous infusion (0.02 ml/kg/min) in two sets of experiments at doses of 0.035, 0.106, and 0.352 mg/kg/min (1.06, 3.17, and 10.56 mg/kg/30 min; high-dose series) and 0.004, 0.012, and 0.04 mg/kg/ min (0.12, 0.36, and 1.20 mg/kg/30 min; low-dose series). Animals were monitored for 1 h after administration of the third dose. Blood samples were collected into standard blood tubes containing heparin, beginning at time 0 and at 15-min intervals throughout the experimental protocol, and stored on ice. Hematocrit was determined at 30-min intervals using microcapillary tubes. Whole blood samples were used in the high-dose series for drug concentration measurements, whereas plasma was used for the low-dose series.
Data are expressed as the group mean Ϯ S.E.M. Statistical analysis was performed by comparison of values from ABT-288 and vehicle-treated dogs at each time point for each variable, using two-sided t tests. In addition, for each parameter at each treatment and post-treatment time point, two-sample, two-sided t tests were used to compare changes from baseline for drug-treated versus vehicle-treated dogs.
A statistical analysis was performed for each parameter at 15-min intervals coinciding with the 10 time points whereby plasma concentrations of ABT-288 were determined. The effect of antagonists on each parameter was analyzed based on the change from baseline within each group during antagonist infusion and the post-treatment period. Specifically, a repeated-measure analysis of variance model was used to analyze the data. The model factors included treatment group, time point, and treatment group by time point interaction. Because the readings at the 10 time points (repeated measures) for each animal were correlated, a heterogeneous autoregression covariance matrix was used to account for the correlation of repeated measurements. The change in each hemodynamic parameter in antagonist-treated animals versus vehicle was also evaluated at each time point when the ANOVA model indicated a significant treatment group by time point interaction (p Ͻ 0.05). All statistical tests and comparisons were assessed at a 0.05 level of significance.
Pharmacokinetic Analysis
ABT-288 was selectively removed from the plasma or brain homogenate by using protein precipitation with acetonitrile at neutral pH. The samples were vortexed vigorously followed by centrifugation. The supernatant was transferred and evaporated to dryness with a gentle stream of nitrogen over low heat (ϳ35°C). The samples were reconstituted by vortexing with mobile phase. ABT-288 and internal standard were separated from c-extracted contaminants on a 5 cm ϫ 3 mm 3-Luna CN column with an acetonitirile/0.1% trifluoroacetic acid (30:70, by volume) mobile phase at a flow rate of 0.4 ml/min with a 25-l injection. ABT-288 was quantified by using multiple reaction monitoring detection, m/z 373.3-Ͼ343.2 using a turbo ionspray source on a PerkinElmerSciex Instruments (Boston, MA) mass spectrometer. The limits for quantification were approximately 1 ng/ml for plasma and 10 ng/g for brain samples. For more sensitive analysis of plasma and brain samples obtained from the H 3 receptor occupancy and behavioral studies, a 5 cm ϫ 3 mm 5-Aquasil C18 (Thermo Fisher Scientific, Waltham, MA) column was used with a 10-l injection volume. All other parameters were the same as described previously . The limits for quantification were approximately 0.08 ng/ml for plasma and 0.25 ng/g for brain samples under these conditions.
Results
Histamine Receptor Binding
The H 3 R binding affinities for ABT-288, ABT-239, and ciproxifan were determined for the full-length recombinant rat or human H 3 Rs as well as for H 3 Rs present in rat, mouse, and human brain cortical membranes (Table 1 ). All three compounds exhibited high affinity for the recombinant rat H 3 R and rodent brain cortical membrane H 3 Rs with K i values less than 10 nM. ABT-288 was 4-to 8-fold more potent at human recombinant (K i ϭ 1.9 nM) and brain cortical (0.64 nM) H 3 Rs than at the corresponding rat receptors in contrast to the more rat-selective H 3 R antagonist ciproxifan (Table 1) . ABT-288 recognized a single high-affinity H 3 R binding site bound by the agonist radioligand [
3 H]N-␣-methylhistamine Fig. 2A) and rat H 3 Rs in a parallel, dextral manner with Schild slopes approaching unity and respective pA 2 values of 8.7 and 8.2 (Table 2 ). In these studies, whereas the basal [
35 S]GTP␥S binding was decreased up to 50% in a concentration-dependent manner by the inverse agonist activity of ABT-288 described below, the maximal agonist response to (R)-␣-MeHA in the presence of ABT-288 was still achieved, indicating the competitive antagonism properties of this compound. The pA 2 values compared favorably to those for ABT-239 at both receptors as was seen in the binding assays, whereas ciproxifan exhibited lower antagonist potency at human H 3 Rs. ABT-288 is also an inverse agonist, reversing basal [
35 S]GTP␥S binding mediated by human and rat H 3 Rs in a concentration-dependent manner with respective EC 50 values of 3.78 and 7.2 nM, equipotent with ABT-239 at both receptors and more potent than ciproxifan at the rat H 3 R ( Table 2) .
Effects of ABT-288 in In Vitro Models of Neurotransmitter Release
ABT-288 exhibited competitive antagonism by shifting the concentration response curves for (R)-␣-MeHA-mediated reversal of EFS contractions of guinea pig ileal segments with a pA 2 value of 9.1, comparable with the potencies exhibited by both ABT-239 and ciproxifan (Table 2 ). In another model of neurotransmitter release, the activation of presynaptic H 3 Rs inhibited the release of [ 3 H]histamine from rat brain synaptosomes caused by potassium-stimulated depolarization. This histamine-mediated reversal of [ 3 H]histamine release from rat synaptosomes was inhibited by ABT-288 in a concentration-dependent manner with a K b value of 3.2 nM (Fig. 2B) , a somewhat greater antagonist potency in this model than that shown by ABT-239 (Table 2) .
Effects of ABT-288 on In Vivo Neurotransmitter Release
ABT-288 dose-dependently increased microdialysate acetylcholine (Fig. 3, top) and dopamine (Fig. 3, middle ) levels in the medial prefrontal cortex. Acetylcholine levels peaked at 40 to 60 min after dosing with an elevation in acetylcholine levels that lasted for up to 2 h seen at the higher doses. A similar profile for acetylcholine release was seen in the hippocampus although the magnitude of the increase in acetylcholine levels was smaller (data not shown). Higher doses of ABT-288 (3.0 and 10.0 mg/kg) were required to increase dopamine levels that also peaked at approximately 40 min after dosing with a sustained elevation seen for up to 2 h. One-way ANOVA for the area under the curve from time 0 to 120 min revealed a significant treatment effect for microdialysate acetylcholine (F 5,49 ϭ 6.41; p Ͻ 0.0002) and dopamine (F 2,27 ϭ 18.84; p Ͻ 0.0001) levels in the medial prefrontal cortex. Subsequent DunnettЈs pairwise comparisons revealed a significant increase of microdialysate acetylcholine (p Ͻ 0.05 at 0.3, 1.0, and 3.0 mg/kg) and dopamine (p Ͻ 0.01 at 3.0 and 10 mg/kg) levels compared with vehicle-treated animals in the medial prefrontal cortex after administration of ABT-288. It is noteworthy that dopamine levels were not increased (Fig. 3, middle, inset) . ABT-288 (0.3 and 1 mg/kg) showed a trend in increasing histamine levels in the medial prefrontal cortex that peaked at 20 min after dosing and remained elevated for up to 2 h after dosing (Fig. 3,  bottom) ; however, one-way ANOVA for the area under the curve from time 0 to 120 min did not reveal a significant treatment effect for microdialysate histamine levels.
Effects of ABT-288 in Rodent Models of Cognition
Five-Trial Inhibitory Avoidance in SHR Pups. ABT-288 treatment 30 min before training produced a significant improved performance compared with vehicle-treated rats (Fig. 4) . Plasma samples collected from a separate set of pups revealed efficacious plasma concentrations of 0.1 to 2.0 ng/ ml. Plasma levels of 1 ng/ml (at 0.01 mg/kg) were considered an indicator of preclinical cognitive efficacy to establish the safety index for this compound. To assess efficacy with repeated dosing, SHR pups were dosed for 5 days with the maximally efficacious dose of ABT-288 (0.01 mg/kg). After 5 days of repeated dosing, the efficacy of ABT-288 was maintained with observed mean crossover latencies of 309 Ϯ 38 s (Ϯ S.E.M.) compared with acute treatment (342 Ϯ 42 s) and vehicle control (175 Ϯ 46 s), suggesting that the development of tolerance is unlikely. In addition, no diminution of the 0.01 mg/kg response was seen when animals were repeatedly dosed at the higher efficacious dose of 0.03 mg/kg for 4 days, then acutely tested on day 5 with the lower effective dose of 0.01 mg/kg (data not shown).
Social Recognition. Overall differences in the ratios of the ABT-288 treatment groups compared with vehicle were evaluated by applying a one-way ANOVA (F 9,83 ϭ 4.574; p Ͻ 0.05) with significance assessed by a subsequent Dunnett's post hoc analysis. ABT-288 produced significant increases in recall performance (expressed as investigation ratio) ratio in the social recognition assay at doses of 0.03 and 0.1 mg/kg i.p., equivalent to that seen with ABT-239 (Fig. 5) . Lower (0.01 mg/kg) and higher (0.3 mg/kg) doses of ABT-288 did not improve performance. To assess efficacy with repeated dosing in this model, rats were dosed for 5 days with 0.03 mg/kg ABT-288. There was no significant difference between repeatedly dosed animals and acutely dosed animals with observed investigation ratios of 0.71 Ϯ 0.06 (mean Ϯ S.E.M.) for the repeatedly dosed treatment and acute treatment (0.62 Ϯ 0.06) compared with vehicle control (0.91 Ϯ 0.06). ABT-288 did not exhibit any nonspecific effects in this task, as evidenced by a lack of an effect on the investigation of a novel juvenile (data not shown), indicating the effects in this model were not caused by general changes in investigational behavior.
Scopolamine Induced Deficit in Rat Two-Platform Discrimination Water Maze. Vehicle-treated rats normally learned the task over 5 days of testing, whereas rats treated with scopolamine (0.3 mg/kg i.p.) exhibited impaired discrimination learning in this assay as demonstrated by a consistent number of errors (contacts with the incorrect, floating platform) across test days (Fig. 6) . Overall differences in errors were evaluated by applying a repeated-measures ANOVA, indicating an overall effect for day (F 4,41 ϭ 6.446; p Ͻ 0.0001), treatment (F 5,41 ϭ 6.268; p ϭ 0.0002) and a significant day ϫ treatment interaction (F 20,41 ϭ 1.753; p ϭ 0.03). For each day, significance was assessed by ANOVA with subsequent post hoc analysis using Bonferroni's method. ABT-288, administered each day of testing, significantly attenuated the scopolamine deficit at doses of 0.1 and 1 mg/kg (Fig. 6 ). This response is comparable with the positive control group dosed with ABT-239 (1 mg/kg), which also significantly attenuated the scopolamine deficit.
Methamphetamine-Induced Hyperactivity. Clinically effective antipsychotic agents can block the long-lasting hyperactivity induced by methamphetamine in rodents. ABT-288 attenuated methamphetamine-induced hyperactivity in a dose-related manner, reaching significance after the administration of 1.0 mg/kg (data collapsed over 90 min after methamphetamine administration; Fig. 7 ). Antipsychotics that are efficacious in this assay, such as risperidone, significantly attenuated methamphetamineinduced hyperactivity.
EEG Slow-Wave Activity
ABT-288 at doses of 0.01 and 0.1 mg/kg i.p. had no significant effect on slow-wave EEG activity for up to 2 h after administration (Fig. 8) . At the highest dose tested (1.0 mg/ kg), ABT-288 significantly decreased the amplitude of the 1-to 4-Hz slow wave (p Ͻ 0.01; Neuman-Keuls multiple comparison test) (Fig. 8) . Corresponding plasma levels of ABT-288 at the two lower doses were 0.9 and 11.2 ng/ml, whereas the plasma level at 1 mg/kg corresponded to 165 ng/ml. In this model, the histamine H 1 antagonist diphenhydramine increased slow-wave activity (Fig. 8) , consistent with its sedative effects in humans.
Receptor Occupancy
ABT-288 inhibited cortical [
3 H]A-349821 H 3 R occupancy as shown in Fig. 9 . At the dose of [
3 H]A-349821 used, cortical H 3 R occupancy was 0.15 fmol/mg tissue, which was equivalent to approximately 1.5% of the total cortical H 3 Rs. The levels of [ 3 H]A-349821 were approximately 2-fold greater in cortexes than cerebellum. In rats pretreated with maximal doses of ABT-288, [ 3 H]A-349821 levels in cortex and cerebellum were indistinguishable, indicating that ABT-288 completely inhibited [ 3 H]A-349821 H 3 R occupancy. ABT-288 occupied cortical H 3 Rs in a dose-dependent manner with an ED 50 of 0.1 mg/kg, and at the dose of 1.0 mg/kg it produced more than 90% occupancy. ABT-288 plasma levels were determined in these studies, and an EC 50 value of 3.17 Ϯ 0.7 ng/ml was calculated from a plasma level-occupancy plot (Fig. 9) .
Cardiovascular Effects
ABT-288 exhibited low affinity for [ 3 H]dofetilide binding to the hERG channel with a K i value of 8830 nM. Blockade of hERG current by ABT-288 in a stably transfected cell line in vitro was characterized with an IC 50 value of 3760 Ϯ 600 ng/ml, more than 3000-fold the preclinical C max of 1 ng/ml. These results contrast with those for ABT-239, which blocked [ 3 H]dofetilide binding and the hERG current more potently (K i ϭ 250 nM and IC 50 ϭ 56 ng/ml, respectively).
Detailed cardiovascular studies were conducted in anesthetized dogs where peak blood concentrations of 570 Ϯ 40, 1870 Ϯ 120, and 6300 Ϯ 330 ng/ml for ABT-288 were achieved at the end of each infusion period corresponding to 570-to 6300-fold above the preclinical efficacious level (1 ng/ml). At the highest concentration tested, ABT-288 produced no physiologically relevant effects on any hemodynamic parameter measured including mean arterial pressure (Fig. 10, top) as well as systolic arterial pressure, diastolic arterial pressure, heart rate, contractility, cardiac output, pulmonary arterial pressure, pulmonary vascular resistance, and systemic vascular resistance, central venous pressure, left ventricular end-diastolic pressure, or hematocrit. At all doses tested and at the highest blood concentration tested (6300 Ϯ 330 ng/ml) and relative to vehicle controls, ABT-288 produced no statistically significant changes in the QT interval corrected for heart rate ( Fig. 10, bottom) .
Pharmacokinetic Properties of ABT-288
The pharmacokinetics of ABT-288 were evaluated in Sprague-Dawley rats and CD-1 mice. ABT-288 exhibited blood clearance (CL␤) values of 1.3 l/h ⅐ kg in mouse and 2.7 l/h ⅐ kg in the rat. ABT-288 exhibited high volumes of distribution, with V ss values of 1.7 l/kg in mouse and 5.3 l/kg in rat. In vitro plasma protein binding of ABT-288 was 86 and 88%, respectively, in mouse and rat. The elimination half-lives for ABT-288 were 1.0 and 1.3 h in mouse and rat, respectively. Rats demonstrated the highest clearance values and correspondingly the lowest bioavailability at approximately 37% after a 1 mg/kg dose in the rat. Mice exhibited higher bioavailability at 66%.
Discussion
Our findings show that ABT-288 is an H 3 R competitive antagonist that potently and selectively binds rat and human H 3 Rs, exhibiting slightly higher affinity toward the human receptor. The high degree of selectivity of ABT-288 is illustrated by its more than 5000-fold greater affinity for the human histamine H 3 R versus other histamine receptor subtypes and its good selectivity against other G protein-coupled receptor and ion channel targets. Functionally, ABT-288 is a competitive antagonist, inhibiting agonist-stimulated H 3 R GTP␥S binding by both rat and human receptors and reversing H 3 R agonist-induced inhibition of neurotransmitter release in in vitro native H 3 R models. Schild analysis of the inhibition of (R)-␣-MeHA-induced GTP␥S binding mediated by H 3 Rs clearly demonstrates the competitive antagonist properties of ABT-288, revealing pA 2 values that approximate the binding affinities. Although ABT-239 binding affinities were somewhat greater than ABT-288, the antagonist potencies of ABT-288 and ABT-239 were similar. Like almost all H 3 R antagonists described to date, ABT-288 is also an H 3 R inverse agonist, potently reversing basal human and rat Total Plasma ABT-288 (ng/ml) % Receptor Occupancy Fig. 9 . ABT-288 occupies rat brain cortical H 3 Rs in a dose-dependent and saturable manner as determined by displacement of systemically administered [ H 3 R constitutive GTP␥S binding activity. Although the inverse agonist effects of ABT-288 described here are in an in vitro recombinant system, it should be noted that H 3 R inverse agonists have also been shown to reduce the activity of native, constitutively active expressed H 3 Rs, decreasing basal GTP␥S binding (Arrang et al., 2007) and enhancing neurotransmitter release in vitro and in vivo (Morisset et al., 2000) .
ABT-288 enhanced the in vitro release of histamine and acetylcholine, two neurotransmitters important for cognition and vigilance (Esbenshade et al., 2008; Haas et al., 2008; Passani et al., 2009) , by potently and competitively reversing H 3 R agonist-mediated inhibition of their release in the rat brain synaptosome and EFS guinea pig ileal segment assays, respectively. This work was extended in vivo, where ABT-288 significantly enhanced acetylcholine and dopamine levels in rat prefrontal cortex. ABT-288 was most potent and efficacious in enhancing acetylcholine release in prefrontal cortex in comparison with hippocampus, where higher doses were required and the magnitude of the effect was lower, and in comparison with histamine and dopamine in the prefrontal cortex where higher doses were required to enhance release. It is noteworthy that GSK189254 enhanced acetylcholine and dopamine levels at equivalent doses in the rat interior cingulate cortex (Medhurst et al., 2007) , perhaps a brain region-specific event. In addition, ABT-288 increased dopamine release only in the prefrontal cortex and not striatum. Although ABT-288 did not significantly increase histamine release in the prefrontal cortex, there was a trend toward enhanced release, consistent with the brain region-specific enhancement of histamine release by the H 3 antagonist GSK189254 (Giannoni et al., 2010) . These findings suggest that the effects of H 3 antagonists on the release of neurotranmitter release probably are not caused by general brain activation but instead are probably more regionally and functionally discrete, dependent on histaminergic innervation and localization of H 3 Rs. Preclinical evidence suggests that histamine H 3 R blockade can decrease impulsivity, improve attention, and enhance learning and memory. Much of the research in these areas has focused on cognition assays that measure the different learning and memory domains thought to be most affected in CNS diseases. ABT-288 was efficacious in three different cognitive tests designed to assess attention, short-term social memory, and spatial cognition. As is often seen with H 3 antagonists, the potency and efficacy of ABT-288 varied depending on the cognitive domain measured. ABT-288 produced a dose-dependent improvement of acquisition in a fivetrial inhibitory avoidance task in SHR pups previously linked to attention/impulsivity deficits (Fox et al., 2002) . Full efficacy was achieved at 0.001 mg/kg and maintained over a broad dose range up to 0.03 mg/kg with corresponding plasma exposure levels of 0.1 to 2.0 ng/ml. It is noteworthy that these exposure levels correspond to an H 3 R occupancy (EC 50 ϭ 3.17 ng/ml) of 10 to 40%, indicating that only a small proportion of H 3 Rs needed to be blocked to achieve efficacy in this model. Although slightly less potent in vitro than ABT-239 at the rat H 3 R, ABT-288 is 100-fold more potent on a dosage basis than ABT-239 in this model, which is reflective of the higher volume of distribution and higher plasma protein binding of ABT-239. It has been reported for GSK189254 and other GlaxoSmithKline compounds that more than 60% H 3 R occupancy is required for efficacy, but it must be recognized that these agents were tested in different behavioral models (passive avoidance and novel object recognition).
ABT-288 was less potent and exhibited a narrower range of efficacious doses in a model of short-term social memory in adult rats than in the five-trial inhibitory avoidance model, with full efficacy achieved at 0.03 to 0.1 mg/kg i.p. Another aspect of cognition that is impaired in patients with AD and schizophrenia is working memory that can be measured with a spatial navigation test in the water maze. ABT-288 reversed scopolamine-induced deficits in this task at 0.1 and 1.0 mg/kg i.p., similar to the doses required for efficacy in the social recognition assay. It is noteworthy that efficacy across the cognitive models is first seen at lower doses (0.001-0.1 mg/kg) of ABT-288 than the dose (1.0 mg/kg) that causes a decrease in the amplitude of 1-to 4-Hz slow waves. This suggests that improvements in cognitive performance occurs at lower levels of H 3 R occupancy than is required for wakefulness, in agreement with an earlier report showing that a high degree of receptor occupancy was required to increased wakefulness by H 3 R antagonists when sleep parameters were measured (Le et al., 2008) . Additional studies seem warranted to determine whether differential neurotransmitter release, different sites or signaling events, or other reasons account for the differences in doses of H 3 R antagonists required for cognitive effects and those that cause EEG activation.
Acetylcholine release in the frontal cortex was the most robust and sensitive (0.3-3 mg/kg) of the three neurotrans- jpet.aspetjournals.org mitters measured, but dopamine levels were also increased at higher doses in the prefrontal cortex, perhaps implicating these neurotransmitters in the cognitive effects of ABT-288. Although the doses required for stimulating release of the neurotransmitters were higher than those required for cognitive effects, probably reflecting the limitations in sensitivity (spatial, temporal resolution) of the microdialysis approach, it is likely that more discreet changes in local levels of these neurotransmitters in general occur after administration of ABT-288. On the other hand, all microdialysis studies reported here have been performed under so-called resting conditions: no behavioral/cognitive challenges or environmental stimuli (Pepeu and Giovannini 2004 ) that may result in limited sensitivity of neurotransmitter release toward H 3 blockade by ABT-288. Social memory is impaired in Alzheimer's disease and schizophrenia (Pinkham et al., 2003) , and both acetylcholine (Winslow and Camacho, 1995) and histamine (Prast et al., 1996) have been implicated as being involved in the social recognition assay. Cholinergic neurotransmission in the hippocampus is integral to spatial memory, and ABT-288 was able to overcome the deficit produced by scopolamine in the water maze task. It is possible that the positive effects of ABT-288 observed across the cognitive domains examined in this study are mediated at least in part by acetylcholine with contributions from histaminergic and dopaminergic systems depending on the doses and brain regions involved in the processes. The effect of ABT-288 in a model related to schizophrenia was also assessed. Current antipsychotics are believed to work through the blockade of dopamine hyperactivity in mesolimbic and mesocortical regions, which is hypothesized to underlie the positive symptoms in schizophrenia. Positive symptoms of schizophrenia are thought to be modeled in the methamphetamine-induced psychomotor hyperactivity rodent test, where antipsychotic drugs have been shown to be efficacious in blocking methamphetamine-induced hyperlocomotion. In these studies, ABT-288 (1.0 mg/kg) blocked the psychostimulant effects of methamphetamine. The efficacious dose of ABT-288 in this model was higher than that required for efficacy in the cognitive models, an effect also seen with ABT-239 . It is noteworthy that GSK207040 did not reverse hyperlocomotion induced by methamphetamine (Southam et al., 2009) , and pitolisant was only partially effective (Ligneau et al., 2007a) .
ABT-288 exhibits good drug-like attributes including favorable pharmacokinetic properties in mouse and rat characterized by moderate to high plasma clearance values and moderate to high volumes of distribution. The plasma elimination half-life was short in rodents (Ͻ1.5 h), but still more than adequate for testing in rodent cognition models. The oral bioavailability values ranged from 37% in rat to 67% in mouse. The brain-to-plasma ratios were greater than 1.5:1 in both mouse and rat, indicating ABT-288 readily partitioned into the brain. In addition, ABT-288 exhibited no appreciable effects in in vitro hERG models or in vivo canine cardiovascular studies at dose multiples of up to 6300-fold over the behaviorally efficacious level in rodents, a margin superior to that previously seen with ABT-239.
ABT-288 is a highly selective H 3 R competitive antagonist with high potency at both rat and human H 3 Rs. ABT-288 modulates neurotransmitter release in vitro, enhances the release of acetylcholine and dopamine in vivo, and exhibits preclinical efficacy in rodent behavioral tests across multiple cognitive domains affected in disorders of cognition such as AD, attention deficit hyperactivity disorder, and cognitive deficits of schizophrenia. ABT-288 exhibits a safe preclinical profile in rodent and dog studies and has advanced to the clinical stage to determine its pharmacokinetics and tolerability in healthy volunteers. ABT-288 is currently in phase 2 trials to evaluate its therapeutic benefit for the treatment of cognitive deficits in Alzheimer's disease and schizophrenia.
